Lisa Glasser

Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019

Brandon J. Patterson, Chi‐Chang Chen, Catherine B. McGuiness et al. · Human Vaccines & Immunotherapeutics · 2021 · 29 citations · Full text

Series Completion, Immunodeficiencies, Vaccine Hesitancy +19

Assessing the risk and costs of COVID-19 in immunocompromised populations in a large United States commercial insurance health plan: the EPOCH-US Study

Amita Ketkar, Vincent J. Willey, Michael Pollack et al. · Current Medical Research and Opinion · 2023 · 29 citations

Assessing the Burden and Cost of COVID-19 Across Variants in Commercially Insured Immunocompromised Populations in the United States: Updated Results and Trends from the Ongoing EPOCH-US Study

Amita Ketkar, Vincent J. Willey, Lisa Glasser et al. · Advances in Therapy · 2024 · 20 citations · Full text

Factors influencing series completion rates of recombinant herpes zoster vaccine in the United States: A retrospective pharmacy and medical claims analysis

Brandon J. Patterson, Chi‐Chang Chen, Catherine B. McGuiness et al. · Journal of the American Pharmacists Association · 2021 · 13 citations

Herpes Zoster Incidence and Burden in Adults With Type 2 Diabetes in the U.S.: A Retrospective Database Analysis

Jean‐Etienne Poirrier, Juliana Meyers, Saurabh Nagar et al. · Diabetes Care · 2022 · 13 citations · Full text